Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
NEW YORK, March 08, 2016 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of INSYS Therapeutics, Inc. securities (NASDAQ:INSY) from March 3, 2015 through January 25, 2016, all dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for INSYS Therapeutics investors under the federal securities laws.
To join the INSYS Therapeutics class action, go to the firm’s website at http://rosenlegal.com/cases-834.html or call Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, Defendants throughout the Class Period issued materially false and misleading statements to investors and/or failed to disclose that: (1) INSYS Therapeutics was engaged in the illegal and improper off-labeling marketing of Subsys; (2) certain INSYS Therapeutics employees were complicit in an illegal kickback scheme operated for the purpose of increasing prescriptions of Subsys; and (3) as a result, INSYS Therapeutics’ financial statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 4, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://rosenlegal.com/cases-834.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
